Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine/samidorphan - Alkermes

Next Previous
X
Search
Drug Profile

Olanzapine/samidorphan - Alkermes

Alternative Names: ALKS 33/olanzapine; ALKS-3831; LYBALVI; Olanzapine/ALKS 33; OLZ/SAM - Alkermes plc; Samidorphan/olanzapine

Latest Information Update: 07 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes plc
  • Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Mood stabilisers; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • No development reported Psychotic disorders

Most Recent Events

  • 07 Jan 2025 Olanzapine/samidorphan is still in phase III trials for Bipolar disorder (In adolescents, In children) in the USA (PO) (NCT03187769)
  • 07 Jan 2025 Olanzapine/samidorphan is still in phase III trials for Bipolar disorder (In children, Treatment-experienced) in the USA (PO) (NCT05303064)
  • 07 Jan 2025 No development reported - Phase-III for Bipolar disorders (In adults, In adolescents) in United Kingdom, Italy, Romania, Poland, Austria, USA, Spain, Ireland, Germany, Russia, Ukraine, Israel, South Korea (PO) (NCT03187769)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top